CHICAGO, Dec. 1, 2013 /PRNewswire/ -- At the 99th Annual Meeting of the Radiological Society of North America (RSNA) in Chicago, Royal Philips (NYSE: PHG, AEX: PHIA) today illustrated its technology leadership in medical imaging with the introduction of two fundamentally new developments: its Vereos PET/CT fully digital positron emission tomography/computed tomography (PET/CT) imaging system, and its IQon Spectral CT1 spectral detector-based computed tomography (CT) imaging system.
These new innovations further expand Philips' integrated radiology product portfolio to deliver advanced image quality, critical information and connectivity for seamless real-time collaboration among clinicians and fast, confident decision making. Philips partners with clinicians to drive the clinical performance and economic value of its solutions to find the shortest path to the best care with the most efficient use of resources.
"We work closely with radiologists to understand their biggest challenges, and incorporate these understandings in the development of innovative products like Vereos PET/CT and IQon Spectral CT to meet their complex imaging needs," said Gene Saragnese, CEO, Imaging Systems at Philips Healthcare. "These innovations demonstrate how Philips is providing radiologists with exceptional quality and accuracy in imaging at low dose rates, helping clinicians to get answers, the first time around, so that they can deliver accurate and more confident diagnoses to patients."
"The timing and precision of disease diagnosis are critical to the successful treatment of many diseases," commented Pablo Ros, M.D., Chairman of the Department of Radiology, University Hospitals Case Medical Center and Case Western Reserve University, Cleveland, Ohio. "With that in mind, we are excited to have contributed to the development of Philips' Vereos digital PET/CT and IQon Spectral CT systems and we will continue to collaborate with Philips to realize the potential of these next generation imaging systems."
PET scans are three-dimensional images that provide insight into what is happening inside the body at the molecular and cellular level. A small amount of radiotracer is injected into the patient prior to the exam, which accumulates in the body's tissue and organs, and decays. The PET detector captures pairs of photons that are emitted from the body during this decay process and forms the image. Based on Philips' proprietary 'Digital Photon Counting' technology, the Vereos PET/CT is the first PET/CT system in the industry to use innovative digital silicon photomultiplier detectors instead of traditional analog detectors, resulting in a step change in performance that includes an approximately two-times increase in sensitivity gain, volumetric resolution and quantitative accuracy compared to analog systems.2 These radical improvements can ultimately be translated into high image quality, increased diagnostic confidence, improved treatment planning and faster workflows.
"Personalized medicine will require a patient-specific picture of the functional processes associated with disease," added Pablo Ros, M.D. "Accurate quantification of processes is therefore an important requirement for functional imaging in diagnosis, therapy and research. The quantitative accuracy and remarkably clear images that the new digital PET/CT system delivers are a key step forward."
In a recent survey, nine out of ten referring physicians preferred Vereos digital PET/CT images over images taken with an analog system.3 Philips has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its digital PET/CT system in the U.S.
IQon Spectral CT1
Philips' second RSNA introduction – its IQon Spectral CT system – is the world's first spectral-detector CT system built from the ground up for spectral imaging. It uses color to identify the composition of an image without involving time-consuming protocols. In the same way that white light is made up of a spectrum of colors, the X-ray beam used in CT scanners also consists of a spectrum of X-ray energies. With the development of a fundamentally new spectral detector that can discriminate between X-ray photons of multiple high and low energies simultaneously, Philips' IQon Spectral CT adds a new dimension to CT imaging, delivering not only anatomical information but also the ability to characterize structures based on their material makeup within a single scan.
After a spectral CT examination, clinicians can interpret the conventional grey-scale anatomical images, and if necessary, access the spectral information that was acquired during the same scan. The IQon Spectral CT system's retrospective on-demand data analysis is made possible via Philips' iPatient platform, allowing clinicians to easily experience the benefits of spectral CT routinely within traditional radiology workflows.
Due to its accessibility, speed and accuracy, CT imaging is widely used in the diagnosis of many different diseases and injuries, totaling approximately 450 million imaging procedures globally per year. Philips has consistently driven innovation in CT, most recently with the introduction of its proprietary Iterative Model Reconstruction (IMR) technology to simultaneously reduce CT radiation dose4 and enhance image quality for a broad range of applications.
Philips at RSNA 2013
Visit Philips at RSNA 2013 at booth #6733 in the North Building, Hall B, of the McCormick Place Convention Center from December 1-6. For additional materials and images of Philips' IQon Spectral CT1 and Vereos PET/CT, and for more information on Philips' portfolio of radiology solutions featured at RSNA 2013, please click on this link.
 The IQon Spectral CT is pending 510(k) and is not available for sale in the U.S. A system with the NanoPanel Prism detector is available for sale in the U.S. for conventional scanning.
 Analog system: Philips GEMINI TF 16.
 Based on a recent survey, commissioned by Philips, among referring oncologists when shown Philips GEMINI TF 16 images (analog system) and Philips Vereos PET/CT images (digital system).
 In clinical practice, the use of IMR may reduce CT patient dose depending on the clinical task, patient size, anatomical location and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task.
For further information, please contact:
Philips Group Communications
Tel.: +31 6 10888824
Tel.: +1 978 760 9007
Tel.: +1 978 273 9692
About Royal Philips:
Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people's lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2012 sales of EUR 24.8 billion and employs approximately 114,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare. News from Philips is located at www.philips.com/newscenter.
Image with caption: "Philips Vereos PET/CT." Image available at: http://photos.prnewswire.com/prnh/20131201/NY25594-a
Image with caption: "Philips Vereos PET/CT." Image available at: http://photos.prnewswire.com/prnh/20131201/NY25594-b
Image with caption: "Philips Vereos PET/CT clinical image." Image available at: http://photos.prnewswire.com/prnh/20131201/NY25594-c
SOURCE Royal Philips